- Open Access
Epigenetics of hypoxic pulmonary arterial hypertension following intrauterine growth retardation rat: epigenetics in PAH following IUGR
- Xue-Feng Xu†1,
- Ying Lv†2,
- Wei-Zhong Gu3,
- Li-Li Tang2,
- Jia-Kai Wei2,
- Li-Yan Zhang2 and
- Li-Zhong Du2Email author
© Xu et al.; licensee BioMed Central Ltd. 2013
- Received: 9 December 2012
- Accepted: 8 February 2013
- Published: 14 February 2013
Accumulating evidence reveals that intrauterine growth retardation (IUGR) can cause varying degrees of pulmonary arterial hypertension (PAH) later in life. Moreover, epigenetics plays an important role in the fetal origin of adult disease. The goal of this study was to investigate the role of epigenetics in the development of PAH following IUGR.
The IUGR rats were established by maternal undernutrition during pregnancy. Pulmonary vascular endothelial cells (PVEC) were isolated from the rat lungs by magnetic-activated cell sorting (MACS). We investigated epigenetic regulation of the endothelin-1 (ET-1) gene in PVEC of 1-day and 6-week IUGR rats, and response of IUGR rats to hypoxia.
The maternal nutrient restriction increased the histone acetylation and hypoxia inducible factor-1α (HIF-1α) binding levels in the ET-1 gene promoter of PVEC in IUGR newborn rats, and continued up to 6 weeks after birth. These epigenetic changes could result in an IUGR rat being highly sensitive to hypoxia later in life, causing more significant PAH or pulmonary vascular remodeling.
These findings suggest that epigenetics is closely associated with the development of hypoxic PAH following IUGR, further providing a new insight for improved prevention and treatment of IUGR-related PAH.
- Pulmonary arterial hypertension
- Endothelial cells
- Intrauterine growth retardation
An adverse intrauterine environment, such as uteroplacental vascular insufficiency and maternal malnutrition, may impact the development of the fetus resulting in fetal growth restriction or intrauterine growth retardation (IUGR) [1, 2]. Their perinatal mortality is four to ten times higher than that of normally grown babies [1, 3]. Moreover, a large number of epidemiological studies reveal that IUGR or low birth weight has been linked to the later development of diseases in adulthood, including type 2 diabetes and hypertension [4–6].
Compared with large for gestational age (LGA) infants, IUGR or small for gestational age (SGA) infants show a significantly greater risk of developing chronic lung disease (CLD) . Premature infants with extremely low birth weight who presented initially with no lung disease or only a mild form of respiratory distress syndrome visible on chest radiograms may have an acute pulmonary hypertension episode and right ventricular dysfunction . Moreover, a transient perinatal insult to the pulmonary circulation could have a persistent effects that, when activated later in life, predisposes to developing significant pulmonary vasoconstriction. These survivors would be at a greater risk of developing pulmonary arterial hypertension (PAH) later in life . Another study demonstrated that hypoxia-induced IUGR rats had important deleterious consequences on the cardiopulmonary function of the offspring later in life, resulting in left ventricular diastolic dysfunction and PAH . Accumulating evidence revealed that IUGR induced by intrauterine adverse environment can cause varying degrees of PAH or pulmonary vascular remodeling.
There is evidence that epigenetics play an important role in the fetal origin of adult disease [11–14]. Epigenetics refers to all heritable changes in phenotype or in gene expression states that are not involved in the DNA sequence itself, including histone modification and DNA methylation . To date, epigenetic regulations in adult onset diseases following IUGR, including type 2 diabetes and hypertension, have been extensively investigated [5, 15–17]. Rexhaj et al. found that in mice maternal undernutrition would induce pulmonary vascular dysfunction in the offspring by a DNA methylation of lung tissue . However, data about whether epigenetic regulation is involved in the pathogenesis of PAH following intrauterine environmental changes is limited.
In a previous study, we found that the epigenetic modification of the endothelial nitric oxide synthase (eNOS) gene in persistent pulmonary hypertension of the newborn (PPHN) rats induced eNOS protein expression . However, the increased eNOS expression did not completely offset the effect of vasoconstrictors, such as endothelin-1 (ET-1), and subsequent development of PPHN [19, 20]. A number of clinical studies demonstrated that increased ET-1 was strongly associated with PAH [21–23]. Similar to the eNOS gene, the ET-1 gene expression was also regulated by epigenetics [24–26]. Some transcription factor binding sites, including hypoxia-inducible factor-1α (HIF-1α), are present in the ET-1 proximal promoter region, of which, HIF-1α is a key transcription factor in the hypoxia-induced ET-1 gene expression [27, 28].
Based on the theory that epigenetics plays an important role in the developmental origins of adult disease, we hypothesized that IUGR induced by nutrient restriction could cause epigenetic modification of the PAH-related genes (ET-1), that persists into later life. These epigenetic changes would induce individuals to be highly sensitive to hypoxia or other stimuli, resulting in PAH or pulmonary vascular remodeling. To better understand the role of epigenetics, we performed this study at a cellular level by magnetic-activated cell sorting (MACS).
Intrauterine growth retardation (IUGR) rat model
Hypoxic pulmonary hypertension rat model
Hypoxic pulmonary hypertension model was established according to our previous experiments [30, 31]. Briefly, 4-week IUGR rats and the age-matched control rats were placed in a normobaric hypoxic chamber with a fraction of inspiratory oxygen concentration of 12% for two weeks. During the experiment, the chamber was opened for 10 minutes every day for feeding and to change the animal cages. After a 2-week hypoxic intervention, rat pulmonary arterial pressure was measured, followed by lung tissue immunohistochemistry and isolation of pulmonary vascular endothelial cells. The control and IUGR rats with hypoxia treatment were labeled as “Control hypoxia” and “IUGR hypoxia”, respectively.
Assessment of pulmonary arterial pressure
The right ventricular systolic pressure (RVSP) was used to reflect pulmonary arterial pressure. Measurement of RVSP of 6-week rats was performed according to our previous report . Briefly, 6-week rats were anesthetized (Urethane, 50 mg/kg, intraperitoneal injection), followed by tracheal intubation and immediately connected to a ventilator with 12% O2 for the hypoxic group, and then the thorax was opened. A catheter connected to a pressure transducer was inserted into the right ventricle, and RVSP was recorded immediately. Normal saline was injected into the right ventricle through the needle at a pressure of 20 cmH2O at room temperature and the lung was flushed. Lungs were dissected once the effluent from the left atrium incision was clear of blood.
Immunohistochemistry and physical measurements
Right lung tissues of different ages were removed, frozen in liquid nitrogen and stored at −80°C for Western blotting. Left lung tissues of different ages were isolated and perfused with ice cold 10% formalin at a pressure of 25 cm H2O and fixed for 24 hours at 4°C. The lung tissues were imbedded in paraffin, sectioned at 4–5 μm, and processed for light microscopic immunohistochemistry as the previously described [19, 30]. Samples were incubated with a primary antibody against smooth muscle specific α-actin (α-SMA, clone: 1A4, Dako) overnight, followed by secondary goat antibody (HRP polymer) for 30 minutes at 37°C. At least eight slides from each lung were taken and then analyzed.
The percentage of pulmonary arterial medial thickness occupied by smooth muscle was determined according to our previous study . Small pulmonary arteries of 50-150 μm in diameter were investigated via a systematic sampling method to evaluate random, non-overlapping calibrated fields for each variable. The terminal bronchioles were used as the independent landmark for selecting small pulmonary arteries . We used Image Pro Plus software (Media Cybernetics) to make the measurements. Tissue slides were analyzed by technician who was without knowledge of the group from which the tissue was taken.
Isolation of pulmonary vascular endothelial cells (PVEC)
Pulmonary vascular endothelial cells (PVEC) were isolated by magnetic-activated cell sorting (MACS) as described earlier . Fresh rat lungs were sliced and then incubated with collagenase A. The suspensions were filtered, centrifuged, and washed three times in phosphate buffer saline (PBS) containing 0.5% bovine serum albumin (BSA) and 2 mM EDTA. The final pellets were resuspended in 100 μl of PBS with 0.5% BSA and 2 mM EDTA per 107 total cells, and then incubated with PECAM-1 (555027, BD) for 15 minutes at 4°C. After washing, anti-PE MicroBeads (130-048-801, Miltenyi Biotec) were added to the cell suspension for 15 minutes at 4°C. The PVEC positively labeled with the magnetic microbeads linked to PECAM-1 antibody were selected with the separation unit, and kept at −80°C until use. The proportion of positive PVEC after MACS was about 92% , there were no significantly statistical difference between groups.
Western blot detection for α-SMA and endothelin-1 proteins
Total protein extracts and protein concentrations were prepared according to our previous studies [19, 30]. Thirty micrograms of protein extracts were resolved on 8-10% SDS polyacrylamide gels for α-SMA (42kDa) and ET-1 (21kDa) proteins. Proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane using a BioRad gel blotting apparatus. Membranes were incubated with a primary antibody against α-SMA and ET-1 overnight at 4°C and with a peroxidase-conjugated secondary antibody for 60 minutes at room temperature. Peroxidase was visualized by enhanced chemiluminescence (ECL) and exposure to ECL films for appropriate times. The bands of Western blots were quantitated by densitometry and normalized with β-actin (42kDa) using Image Pro Plus software. Protein level is expressed as a percentage of normal control ± standard error of the mean (SEM).
Quantitative real-time PCR for ET-1
Total RNA was isolated from PVECs according to the RNeasy protocol (Axygen). RNA was reverse-transcribed using a reverse transcriptase kit (TAKARA) according to manufacturer’s protocols. Real-time quantitative PCR was performed by the ABI Prism 7500 Instrument following the TAKARA protocol. β-actin was used as an internal control. Primers for ET-1 and β-actin are as follows: forward: 5’-aagcagacaaagaactccgag-3’, reverse: 5’-cgctttcaactttgcaactcg-3’; forward: 5’-gccaaccgtgaaaagatg-3’, reverse: 5’-tgccagtggtacgaccag-3’, respectively.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was performed as described in a previous study . After the isolated PVEC were fixed and cross-linked, the cell pellets were suspended in cell lysis buffer and centrifuged, and the supernatants were discarded. The pellets were resuspended in SDS lysis buffer, sonicated, centrifuged and aliquots of soluble chromatin were collected. Aliquots of the supernatants were retained for representing the input chromatin. Aliquots were incubated overnight at 4°C with one of the following antibodies: 5 μl anti-acetylaled Histone H3 (06–599, Millipore), 5 μl anti-acetylated Histone H3 (Lys9/18) (H3K9/18, 07–593, Millipore), 5 μl anti-acetylaled Histone H4 (06–866, Millipore), anti-Hypoxia Inducible Factor 1 α (MAB5382, Millipore). The immune complexes were precipitated with Protein A beads and then eluted. The input, unbound and bound fractions were incubated with 5 M NaCl to reverse crosslink. The DNA fragments were purified using the Qiaquick PCR Purification kit (QIAGEN). The DNA fragments containing ET-1 site-specific sequences were quantified by real-time PCR. Relative quantification of PCR products were based on value differences between the bound and input using the △△Ct method. The PCR primers for the ET1 gene promoter were as follows: ET1 promoter A1, F5’-ttgcctgtgggtgactaatc-3’, R5’-ccttcaccggagcgaaag-3’ (−197 to +25); ET1 promoter A2, F5’-cctcttgattcttgaactctggg-3’, R5’-attagtcacccacaggcaac-3’ (−397 to −179).
Values are expressed as mean ± SEM (standard error of mean). The continuous variables in the different groups were compared by one-way ANOVA. Multiple comparisons were performed utilizing the Student-Newman-Keuls test. A difference of P < 0.05 was considered to be statistically significant.
Establishment of rat IUGR model
In the present study, the 10th and 90th percentiles for normal newborn rat birth weight were 5.87 g and 7.60 g, respectively. Newborn rats weighing less than 5.80 g were considered to be IUGR. The average birth weight of normal newborn rats (n = 276) was 6.80 g ± 0.044 g, while the average birth weight of newborn rats from the diet restricted group (n = 305) was 5.10 g ± 0.037 g. There was statistically significant difference between the two groups (P < 0.001). The sampling age of different experimental group rats were seen in Figure 1.
Right ventricular systolic pressure (RVSP) of 6-week, hypoxia-treated rats
Pulmonary histological changes in 1-day, 6-week, hypoxia-treated rats
The percentage of medial thickness in small pulmonary arteries of 50–150 μm diameter was analyzed. The medial/(medial + lumen) thickness ratios of IUGR d1 group rats were lower than those of Control d1 group rats, but there was no statistically significant difference between the two groups (0.2678 ± 0.012 versus 0.2384 ± 0.013, P = 0.152). Although the medial thickness ratios of IUGR 6wks group rats were slightly higher than those of age-matched control rats, there was no statistically significant difference between the two groups (0.3397 ± 0.011 versus 0.3393 ± 0.015, P = 0.986).
Lung tissue α-SMA levels
Endothelin −1 (ET-1) expression of PVEC
Although the ET-1 protein level of the IUGR d1 group was higher than the age-matched control group, there was no significantly statistical significance (P > 0.05, Figure 4B). The ET-1 protein level of the IUGR 6wks group was similar to that of the Control 6wks group, there was no significant difference (P > 0.05). However, the ET-1 expression level in the IUGR hypoxia group was significantly higher than that in Control hypoxia group, and there was a statistically significant difference between the two groups (P = 0.02). Similar to protein expression pattern, the ET-1 mRNA expression showed a similar trend (Figure 4C). These results indicate that the increased ET-1 level of IUGR hypoxia group rats might be responsible for the increased RVSP and pulmonary vascular remodeling changes.
The ET-1 gene promoter histone code of PVEC
Hypoxia inducible factor-1α (HIF-1α) enrichment in ET-1 gene promoter of PVEC
To explore the role of transcription factor HIF-1α in hypoxia-induced pulmonary hypertension, HIF-1α binding levels of the ET-1 gene promoter in PVEC between the IUGR and control groups were analyzed. The HIF-1α binding levels in the ET-1 gene promoter A1 region from the IUGR d1, 6wks and hypoxia groups were higher than the age-matched control groups, and there were statistically significantly statistical differences (P < 0.05, Figure 6B). There were also similar changes in HIF-1α binding levels of the ET-1 gene promoter A2 region, except between the IUGR d1 and Control d1 groups.
The ChIP experiments revealed that histone acetylation modification of the ET-1 gene promoter in IUGR rats might induce transcription factor HIF-1α accumulation in the ET-1 promoter region, which would lead to the ET-1 gene transcription and protein expression.
The ‘histone code’ hypothesis proposes that covalent modifications of the histone proteins contribute to transcriptional regulation. These histone modifications provide a mechanism that allows encoding information of successive generations of cell division [33, 34]. Generally, increased levels of histone acetylation are associated with increased transcriptional activity, whereas decreased levels of acetylation are correlated with suppressed gene expression. Our data demonstrate that the open chromatin domains marked by histone H3 and H3K9/18 acetylation at the proximal promoter of ET-1 in IUGR rats are essential for transcription. Upregulated ET-1 protein expression in PVEC from IUGR hypoxia rats is closely associated with the presence of increased acetylated H3 histones. Reduction of these markers in Control hypoxia rats results in the decreased ET-1 protein expression.
In the present study, PVEC isolated from IUGR day1 rats shows a significant increase in H3 and H3K9/18 acetylation at the proximal promoter of ET-1, and can be continued until 6 weeks after birth. These epigenetic markers would contribute to the higher sensitivity in IUGR rats in later life to hypoxia, leading to more pronounced PAH or pulmonary vascular remodeling than the normal rats. The increased histone acetylation of the ET-1 gene in the IUGR hypoxia rats up-regulated ET-1 protein expression, inducing a more significant PAH. In general, histone acetylation will lead to increase in gene expression. However, under normal oxygen conditions, although ET-1 protein expression in IUGR newborn rats was higher than age-matched control group, there was no significant difference between the two groups. Moreover, ET-1 protein level in 6-week IUGR rats was similar to the age-matched control group. The ET-1 protein expression mode in part explained the fact that 6-week IUGR rats, under normoxia, did not produce more significant pulmonary arterial pressure and pulmonary vascular remodeling than the age-matched control rats. Our data demonstrates that the histone acetylation of the ET-1 gene in 6-week IUGR rats is not enough to cause ET-1 protein expression. In addition to histone acetylation, other epigenetic alterations including RNA interference might also be involved in regulation of the ET-1 gene to suppress expression of ET-1 protein. While these possible epigenetic modifications would be likely to induce ET-1 protein expression only in specific stress situations. However, this balance was broken by hypoxia intervention. The ET-1 protein level of PVEC from the IUGR hypoxia group was significantly higher than Control hypoxia group. The up-regulated ET-1 protein level was consistent with increased RVSP and pulmonary vascular remodeling observed in IUGR hypoxia rats. The molecular mechanism responsible for the increased ET-1 protein expression in IUGR hypoxia rats is likely to be strongly related to the recruitment of hypoxia-induced transcriptional factors in the activated (increased histone acetylation) ET-1 promoter, especially the recruitment of HIF-1α.
A previous report demonstrated that in mice undernutrition during gestation would induce pulmonary vascular dysfunction in the offspring by a DNA methylation of lung tissue . Different from their study at a tissue level, we focused on a cellular level to investigate the role of epigenetics of the special gene in development of hypoxic PAH following IUGR. Whether RNA interference, DNA methylation, or other hypoxia-induced transcription factors were involved in development of hypoxic PAH following IUGR, whether these epigenetic changes were maintained into next generation or could be reversed, would deserve further investigation.
In summary, we found that hypoxia induced IUGR rats experience significant PAH and pulmonary vascular remodeling. The response characteristics of IUGR to hypoxia were strongly correlated with the increased histone acetylation and HIF-1α binding levels in the ET-1 gene core promoter region. These findings suggest that epigenetics are closely associated with the development of hypoxic PAH following IUGR, further providing a new insight for improved prevention of IUGR-related PAH.
This work was supported by grants from the National Natural Science Foundation of China (No. 81070512, 81270723, and 81270722) and National Key Technology R&D Program 2012BAI04B04. We thank Drs. Rene Lee and Valerie Sheppard from Loma Linda University Children’s Hospital for reviewing this manuscript. We also thank Zhejiang Key Laboratory for Diagnosis and Therapy of Neonatal Diseases, Key Laboratory of Reproductive Genetics Ministry of Education, and Bioelectromagnetics Laboratory of Zhejiang University School of Medicine for their assistance.
Sources of funding
This work was supported by grants from the National Natural Science Foundation of China (No. 81070512, 81270723, and 81270722).
- Chiswick ML: Intrauterine Growth-Retardation. Br Med J. 1985, 291: 845-848. 10.1136/bmj.291.6499.845.View ArticleGoogle Scholar
- Schwitzgebel VM, Somm E, Klee P: Modeling intrauterine growth retardation in rodents: Impact on pancreas development and glucose homeostasis. Mol Cell Endocrinol. 2009, 304: 78-83. 10.1016/j.mce.2009.02.019.PubMedView ArticleGoogle Scholar
- Gardosi JO, Mongelli JM, Mul T: Intrauterine growth retardation. Baillieres Clin Obstet Gynaecol. 1995, 9: 445-463. 10.1016/S0950-3552(05)80374-8.PubMedView ArticleGoogle Scholar
- Bogdarina I, Welham S, King PJ, Burns SP, Clark AJL: Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ Res. 2007, 100: 520-526. 10.1161/01.RES.0000258855.60637.58.PubMedPubMed CentralView ArticleGoogle Scholar
- Park JH, Stoffers DA, Nicholls RD, Simmons RA: Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1. J Clin Invest. 2008, 118: 2316-2324.PubMedPubMed CentralGoogle Scholar
- Vickers MH, Breier BH, Cutfield WS, Hofman PL, Gluckman PD: Fetal origins of hyperphagia, obesity, and hypertension and postnatal amplification by hypercaloric nutrition. Am J Physiol Endocrinol Metab. 2000, 279: E83-E87.PubMedGoogle Scholar
- Lal MK, Manktelow BN, Draper ES, Field DJ: Chronic lung disease of prematurity and intrauterine growth retardation: A population-based study. Pediatrics. 2003, 111: 483-487. 10.1542/peds.111.3.483.PubMedView ArticleGoogle Scholar
- Danhaive O, Margossian R, Geva T, Kourembanas S: Pulmonary hypertension and right ventricular dysfunction in growth-restricted, extremely low birth weight neonates. J Perinatol. 2005, 25: 495-499. 10.1038/sj.jp.7211299.PubMedView ArticleGoogle Scholar
- Sartori C, Allemann Y, Trueb L, Delabays A, Nicod P, Scherrer U: Augmented vasoreactivity in adult life associated with perinatal vascular insult. Lancet. 1999, 353: 2205-2207. 10.1016/S0140-6736(98)08352-4.PubMedView ArticleGoogle Scholar
- Rueda-Clausen CF, Morton JS, Davidge ST: Effects of hypoxia-induced intrauterine growth restriction on cardiopulmonary structure and function during adulthood. Cardiovasc Res. 2009, 81: 713-722.PubMedView ArticleGoogle Scholar
- Fu Q, McKnight RA, Yu X, Callaway CW, Lane RH: Growth retardation alters the epigenetic characteristics of hepatic dual specificity phosphatase 5. FASEB J. 2006, 20: 2127-2129. 10.1096/fj.06-6179fje.PubMedView ArticleGoogle Scholar
- Simmons RA: Developmental origins of beta-cell failure in type 2 diabetes: The role of epigenetic mechanisms. Pediatr Res. 2007, 61: 64r-67r. 10.1203/pdr.0b013e3180457623.PubMedView ArticleGoogle Scholar
- Cutfield WS, Hofman PL, Mitchell M, Morison IM: Could epigenetics play a role in the developmental origins of health and disease?. Pediatr Res. 2007, 61: 68R-75R. 10.1203/pdr.0b013e318045764c.PubMedView ArticleGoogle Scholar
- Pham TD, MacLennan NK, Chiu CT, Laksana GS, Hsu JL, Lane RH: Uteroplacental insufficiency increases apoptosis and alters p53 gene methylation in the full-term IUGR rat kidney. Am J Physiol Regul Integr Comp Physiol. 2003, 285: R962-970.PubMedView ArticleGoogle Scholar
- Xu XF, Du LZ: Epigenetics in neonatal diseases. Chinese Medicine Journal. 2010, 123: 2948-2954.Google Scholar
- Fu Q, Yu X, Callaway CW, Lane RH, McKnight RA: Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene. FASEB J. 2009, 23: 2438-2449. 10.1096/fj.08-124768.PubMedPubMed CentralView ArticleGoogle Scholar
- Raychaudhuri N, Raychaudhuri S, Thamotharan M, Devaskar SU: Histone code modifications repress glucose transporter 4 expression in the intrauterine growth-restricted offspring. J Biol Chem. 2008, 283: 13611-13626. 10.1074/jbc.M800128200.PubMedPubMed CentralView ArticleGoogle Scholar
- Rexhaj E, Bloch J, Jayet PY, Rimoldi SF, Dessen P, Mathieu C, Tolsa JF, Nicod P, Scherrer U, Sartori C: Fetal programming of pulmonary vascular dysfunction in mice: role of epigenetic mechanisms. Am J Physiol Heart Circ Physiol. 2011, 301: H247-252. 10.1152/ajpheart.01309.2010.PubMedView ArticleGoogle Scholar
- Xu XF, Ma XL, Shen Z, Wu XL, Cheng F, Du LZ: Epigenetic regulation of the endothelial nitric oxide synthase gene in persistent pulmonary hypertension of the newborn rat. J Hypertens. 2010, 28: 2227-2235. 10.1097/HJH.0b013e32833e08f1.PubMedView ArticleGoogle Scholar
- Xu XF, Cheng F, Du LZ: Epigenetic regulation of pulmonary arterial hypertension. Hypertens Res. 2011, 34: 981-986. 10.1038/hr.2011.79.PubMedView ArticleGoogle Scholar
- Cacoub P, Dorent R, Nataf P, Carayon A, Riquet M, Noe E, Piette JC, Godeau P, Gandjbakhch I: Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res. 1997, 33: 196-200. 10.1016/S0008-6363(96)00189-7.PubMedView ArticleGoogle Scholar
- Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993, 328: 1732-1739. 10.1056/NEJM199306173282402.PubMedView ArticleGoogle Scholar
- Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP, Hoeffken G: Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001, 120: 1562-1569. 10.1378/chest.120.5.1562.PubMedView ArticleGoogle Scholar
- Yeligar S, Tsukamoto H, Kalra VK: Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1alpha and microrNA-199. J Immunol. 2009, 183: 5232-5243. 10.4049/jimmunol.0901084.PubMedPubMed CentralView ArticleGoogle Scholar
- Gonsalves C, Kalra VK: Endothelin-1-induced macrophage inflammatory protein-1beta expression in monocytic cells involves hypoxia-inducible factor-1alpha and AP-1 and is negatively regulated by microRNA-195. J Immunol. 2010, 185: 6253-6264. 10.4049/jimmunol.1000660.PubMedView ArticleGoogle Scholar
- Teplyakov AI: Epigenetic topography of lymphocyte nuclei and endothelin-1 at atherosclerosis. J Cardiovasc Pharmacol. 2004, 44 (Suppl 1): S490-491.PubMedView ArticleGoogle Scholar
- Hu J, Discher DJ, Bishopric NH, Webster KA: Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun. 1998, 245: 894-899. 10.1006/bbrc.1998.8543.PubMedView ArticleGoogle Scholar
- Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA: Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem. 2001, 276: 12645-12653. 10.1074/jbc.M011344200.PubMedView ArticleGoogle Scholar
- Wang X, Liang L, Du L: The effects of intrauterine undernutrition on pancreas ghrelin and insulin expression in neonate rats. J Endocrinol. 2007, 194: 121-129. 10.1677/JOE-07-0057.PubMedView ArticleGoogle Scholar
- Xu XF, Gu WZ, Wu XL, Li RY, Du LZ: Fetal pulmonary vascular remodeling in a rat model induced by hypoxia and indomethacin. J Matern Fetal Neonatal Med. 2011, 24: 172-182. 10.3109/14767058.2010.482608.PubMedView ArticleGoogle Scholar
- Wu X, Du L, Xu X, Tan L, Li R: Increased nitrosoglutathione reductase activity in hypoxic pulmonary hypertension in mice. J Pharmacol Sci. 2010, 113: 32-40. 10.1254/jphs.09279FP.PubMedView ArticleGoogle Scholar
- Hsia CC, Hyde DM, Ochs M, Weibel ER: An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med. 2010, 181: 394-418. 10.1164/rccm.200809-1522ST.PubMedView ArticleGoogle Scholar
- Turner BM: Cellular memory and the histone code. Cell. 2002, 111: 285-291. 10.1016/S0092-8674(02)01080-2.PubMedView ArticleGoogle Scholar
- Strahl BD, Allis CD: The language of covalent histone modifications. Nature. 2000, 403: 41-45. 10.1038/47412.PubMedView ArticleGoogle Scholar
- Ke Q, Costa M: Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006, 70: 1469-1480. 10.1124/mol.106.027029.PubMedView ArticleGoogle Scholar
- Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000, 88: 1474-1480.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.